mRNA |
SNX-2112:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.0003 |
mRNA |
tanespimycin:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.0004 |
mRNA |
BRD-K61166597 |
CTRPv2 |
pan-cancer |
AAC |
-0.09 |
0.004 |
mRNA |
navitoclax:piperlongumine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.004 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.006 |
mRNA |
selumetinib:UNC0638 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.093 |
0.007 |
mRNA |
ML050 |
CTRPv2 |
pan-cancer |
AAC |
0.099 |
0.008 |
mRNA |
Gemcitabine |
CTRPv2 |
pan-cancer |
AAC |
-0.087 |
0.008 |
mRNA |
selumetinib:BRD-A02303741 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.092 |
0.008 |
mRNA |
Merck60 |
CTRPv2 |
pan-cancer |
AAC |
-0.079 |
0.008 |